Page 1002 - Read Online
P. 1002

Agbo et al. J Cancer Metastasis Treat 2019;5:x  I  http://dx.doi.org/10.20517/2394-4722.2019.35                                Page 3 of 11

               Table 1. The characteristics of human samples
                Sample ID           Age             Sex       Tissue type/area   Stage         Ethnicity
                SB-036               64            Male         NSC TSC           IVB          Caucasian
                SB-122               41            Male         NR TR             IV           Caucasian
                SB-124               72            Male         NAC TAC           IV           Caucasian
                SB-130               72            Female       NSC TSC           IV           Caucasian
                SB-263               52            Male         NCE TCE           IV           Caucasian
                SB-378               36            Male         NCE TCE           IV           Caucasian
                SB-474               85            Female       NAC TAC           IV           Caucasian
                SB-337               75            Male         NCE TCE           IIIC         Caucasian
                SB-396               51            Male         NSC TSC           IIIA         Caucasian
                SB-555               40            Male         NCE TCE           IV           Caucasian
                SB-645               38            Male         NSC TSC           I            Caucasian
                SB-670               65            Male         NSC TSC           IIA          Caucasian

               NSC: normal sigmoid colon; TSC: tumor sigmoid colon; NR: normal rectum; TR: tumor rectum; NAC: normal ascending colon; TAC: tumor
               ascending colon; NCE: normal cecum; TCE: tumor cecum

               New York at Stony Brook on 17 October 2014 (CORIHS 2014-2821-F) and qualified for a waiver under the
               Federal Law of Department of Health and Human Services per article 45CFR46.116.d.

               Mice
               All animal studies were approved by the Stony Brook University Institutional Animal Care and Use
               Committee and performed in accordance with institutional policies and NIH guidelines. Mice with the
                                 fl/fl
                                                          [12]
               floxed Klf4 gene (Klf4 ) were described previously . These mice were derived from a C57BL/6 background
               and are indistinguishable from the wild-type mice.

               Azoxymethane and dextran sodium sulfate treatment
               Azoxymethane (AOM) and dextran sodium sulfate (DSS) treatment was performed as described
                        [18]
                                                                 fl/fl
               previously . Briefly, adult gender- and age-matched Klf4  mice (n = 16) were injected intraperitoneally
               with 10 mg/kg of AOM working solution. After seven days, normal water was replaced with 2.5% DSS in
               the drinking water for five days, followed by two weeks of recovery (with normal water). This was followed
               by a second cycle of 2.5% DSS for five days, with two weeks of recovery (with normal water). The mice were
               euthanized at the end of the last recovery treatment, and samples were collected for pathologic analysis.

               Tissue harvesting and tumor assessment, preparation, and immunostaining
               Tissues were collected and prepared for immunofluorescence as described previously . Briefly, tissue
                                                                                           [18]
               sections were baked in a 65 °C oven overnight, deparaffinized in xylene, and rehydrated by incubation in a
               decreasing ethanol bath series (100%, 95%, and 70%), followed by antigen retrieval in citrate buffer solution
               (10 mM sodium citrate and 0.05% Tween-20, pH 6.0) at 120 °C for 10 min using a decloaking chamber
               (Biocare Medical) and 30 min incubation at 4 °C. The histological sections were incubated with blocking
               buffer (5% bovine serum albumin and 0.01% Tween 20 in 1 × Tris-buffered phosphate-buffered saline) for 1
               h at 37 °C. The primary antibodies goat anti-KLF4 (1:200 for human sections and 1:300 for mice sections;
               R&D: AF3158), mouse anti-PanCK (1:200 for human sections; Biocare Medical: AE1/AE3), rabbit anti-β-
               catenin (1:500 for human sections and 1:150 for mice sections; Cell Signaling: 8480), rabbit anti-TWIST
               (1:500; Abcam: ab49254), rabbit anti-Claudin-1 (1:500; Cell Signaling: 13255), rabbit anti-N-cadherin
               (1:500; Cell Signaling: 13116), rabbit anti-E-cadherin (1:300 for mice sections, Cell Signaling: 3195), rabbit
               anti-Vimentin (1:500 for human sections and 1:100 for mice sections; Cell Signaling: 5741), and rabbit
               anti-SNAI2 (1:500 for human sections and 1:400 for mice sections, Cell Signaling: 9585) were added and
               incubated at 4 °C overnight. For KLF4, secondary unconjugated bovine anti-goat antibody was added at
               1:500 dilution in blocking buffer for 30 min at 37 °C. For human sections to stain for PanCK, secondary
               unconjugated chicken anti-mouse antibody was added at 1:500 dilution in blocking buffer for 30 min at 37
   997   998   999   1000   1001   1002   1003   1004   1005   1006   1007